Publication | Closed Access

Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations

Drug TargetE459k Bcr-abl MutationMedicineReceptor Tyrosine KinaseRational Drug DesignMechanism Of ActionMolecular BiologyMutagenesisStructural ModelingPharmacologyMolecular ModelingDrug DiscoverySequential Therapy